Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye implant could replace daily drops for glaucoma patients

NCT ID NCT04060758

Disease control Sponsor: PolyActiva Pty Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a tiny implant placed inside the eye that slowly releases medication to lower eye pressure in people with mild-to-moderate open-angle glaucoma. The goal was to find a dose that works well with few side effects. 37 adults took part, and researchers monitored safety and pressure-lowering effects over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

37 people

The number who actually took part.

Started

Mar 2020

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants who: * Diagnosis of primary open angle glaucoma. * Unmedicated 8:00am IOP ≥ 24 mmHg and ≤ 36mmHg in the intent to treat eye. Additionally, the IOP at 12:00 and 16:00 hrs must be ≥ 20mmHg and ≤ 36mmHg. * Corrected visual acuity in each eye greater than or equal to +0.3logMAR. * Minimum central endothelial cell density of greater than or equal to 1600 cells per mm2 * Currently managing their POAG with IOP lowering drop therapy. Exclusion Criteria: Participants who: * Have pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. * Have a history of or current ocular inflammation. * Have aphakic eyes or only one eye. * Recent surgery in the study eye surgery (including laser). * Clinically significant ocular disease in either eye (e.g., corneal oedema, uveitis, severe keratoconjunctivitis sicca or infection) which might interfere with the study. * Known sensitivity to any component of the product (e.g. latanoprost or polytriazole sensitivity), or to topical therapy used during course of study (e.g. povidone iodine, or anaesthetics). * Ocular medication in either eye of any kind within 30 days of screening. * Central corneal thickness in either eye that is less than 470 µm or greater than 630 µm at screening (or a difference between the eyes \>70 µm). * Any abnormality in either eye preventing reliable applanation tonometry, including aphakic eyes or significant corneal guttatae. * Any other clinically significant disease (as determined by physician) which might interfere with the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open angle glaucoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open angle glaucoma

Contacts and locations

Locations

  • Bendigo Eye Clinic

    Bendigo, Victoria, 3550, Australia

  • Capital Eye Specialists

    Te Aro, 6011, New Zealand

  • Centre for Eye Research Australia

    East Melbourne, Victoria, 3002, Australia

  • Essendon Eye Clinic

    Essendon, Victoria, 3040, Australia

  • Eye Surgery Associates

    Vermont South, Victoria, 3133, Australia

  • Eyes First

    Springvale, Victoria, 3171, Australia

  • Goodwood Eye Centre

    Millswood, South Australia, 5034, Australia

  • Melbourne Eye Specialists

    Fitzroy, Victoria, 3065, Australia

  • PersonalEYES

    Castle Hill, New South Wales, 2150, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.